Thermo Fisher Scientific (NYSE:TMO) Upgraded by HSBC to "Strong-Buy" Rating

Key Points

• HSBC upgraded Thermo Fisher Scientific to “strong buy” from “hold,” while broader analyst sentiment remains positive with a consensus “moderate buy” rating and an average price target of $619.41.
• Thermo Fisher exceeded quarterly expectations, reporting $6.03 in EPS versus $5.71 expected and $11.99 billion in revenue versus $11.71 billion forecast; revenue increased 10.5% year over year.
• Shares opened at $600.32 after declining 2.7%, while company insiders sold $44.1 million of stock during the latest quarter, including significant sales by two executives.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) was upgraded by research analysts at HSBC from a "hold" rating to a "strong-buy" rating in a research report issued to clients and investors on Tuesday, Zacks reports.

TMO has been the topic of a number of other research reports. Sanford C. Bernstein assumed coverage on shares of Thermo Fisher Scientific in a research report on Friday, June 26th. They issued a "market perform" rating and a $520.00 price objective on the stock. Barclays raised their target price on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an "overweight" rating in a research note on Friday, July 24th. Stifel Nicolaus set a $650.00 price target on shares of Thermo Fisher Scientific in a report on Wednesday, August 5th. Weiss Ratings upgraded Thermo Fisher Scientific from a "hold (c)" rating to a "hold (c+)" rating in a report on Friday. Finally, Jefferies Financial Group reissued a "buy" rating and issued a $630.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and a consensus target price of $619.41.

Thermo Fisher Scientific Trading Down 2.7%

Shares of NYSE:TMO opened at $600.32 on Tuesday. The company has a market capitalization of $221.97 billion, a PE ratio of 32.29, a P/E/G ratio of 2.58 and a beta of 0.85. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific has a 12-month low of $435.27 and a 12-month high of $647.00. The business's fifty day simple moving average is $564.35 and its 200-day simple moving average is $512.92.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping analysts' consensus estimates of $5.71 by $0.32. The firm had revenue of $11.99 billion during the quarter, compared to analysts' expectations of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm's quarterly revenue was up 10.5% on a year-over-year basis. During the same period in the prior year, the business posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities research analysts predict that Thermo Fisher Scientific will post 25.13 earnings per share for the current fiscal year.

Insider Transactions at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 420 shares of Thermo Fisher Scientific stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the completion of the sale, the chief accounting officer owned 2,966 shares of the company's stock, valued at $1,734,546.46. The trade was a 12.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Michael D. Shafer sold 25,500 shares of the company's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total value of $15,300,000.00. Following the completion of the sale, the executive vice president owned 20,994 shares in the company, valued at approximately $12,596,400. This represents a 54.85% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 73,768 shares of company stock worth $44,122,820. 0.33% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. California State Teachers Retirement System grew its position in Thermo Fisher Scientific by 49,331.5% during the 2nd quarter. California State Teachers Retirement System now owns 282,654,735 shares of the medical research company's stock worth $141,711,778,000 after purchasing an additional 282,082,924 shares during the period. J. Stern & Co. LLP boosted its stake in shares of Thermo Fisher Scientific by 58,006.4% in the fourth quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company's stock worth $18,258,082,000 after buying an additional 31,455,105 shares during the last quarter. BlackRock Inc. acquired a new stake in Thermo Fisher Scientific during the second quarter worth about $15,501,867,000. Corient Private Wealth LP purchased a new position in Thermo Fisher Scientific during the second quarter valued at approximately $382,547,000. Finally, Norges Bank acquired a new position in Thermo Fisher Scientific in the fourth quarter valued at approximately $3,072,744,000. Hedge funds and other institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source